Study shows reduced neutralizing antibody activity induced by Pfizer–BioNTech vaccine against SARS-CoV-2 variants of concern B.1.617.2 (Delta) and B.1.351 (Beta).

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2  and B.1.351 (Beta) by BNT162b2 vaccination – The Lancet

Commentary: Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant – The Francis Crick Institute

Commentary on Twitter (thread – click for more)

“Immune escape” in #DeltaVariant. That’s the latest finding – that #B16172 is as bad for antibody neutralization as the Beta variant #B1351 from South Africa ??. 1st dose alone very small effect— 2 doses needed, but weakest against Delta. Let’s walk through evidence ? #COVID19 https://t.co/GurgkNVgiY pic.twitter.com/o0s9WIudCW

— Eric Feigl-Ding (@DrEricDing) June 5, 2021